Quince Therapeutics (QNCX) call put ratio 31 calls to 1 put as share price up 40% Feb 11, 2026 02:20PM
Maxim Group Downgrades Quince Therapeutics Inc. (QNCX) to Hold Jan 30, 2026 12:21PM
Lucid Capital Markets Double Downgrades Quince Therapeutics Inc. (QNCX) to Sell, Target to $0 Jan 30, 2026 07:45AM
D. Boral Capital Downgrades Quince Therapeutics Inc. (QNCX) to Hold Jan 30, 2026 07:01AM
Citizens Downgrades Quince Therapeutics Inc. (QNCX) to Market Perform Jan 30, 2026 12:59AM


Jan 29, 2026 03:07PM Quince Therapeutics (QNCX) Halted, News Pending
Jan 22, 2026 05:00AM Quince Therapeutics (QNCX) Reiterated at Market Outperform by Citizens
Jan 9, 2026 04:37AM Citizens Reiterates Market Outperform Rating on Quince Therapeutics Inc. (QNCX)
Jan 6, 2026 05:16AM Quince Therapeutics (QNCX) Reiterated at Market Outperform by Citizens
Dec 11, 2025 04:15AM Quince Therapeutics (QNCX) Reiterated at Market Outperform by Citizens
Dec 10, 2025 04:08PM Quince Therapeutics publishes eDSP study data in pulmonary, IBD disorders
Nov 13, 2025 06:30AM Cortexyme, Inc. (QNCX) Misses Q3 EPS by 3c
Oct 9, 2025 04:07PM Quince Therapeutics presents walking capacity data for rare disease
Oct 3, 2025 04:10AM Citizens Reiterates Market Outperform Rating on Quince Therapeutics Inc. (QNCX)
Sep 26, 2025 04:23AM Citizens JMP Reiterates Market Outperform Rating on Quince Therapeutics Inc. (QNCX)
Sep 25, 2025 04:05PM Quince Therapeutics publishes eDSP pharmacokinetic modeling study
Aug 12, 2025 04:18AM Quince Therapeutics Inc. (QNCX) PT Lowered to $8 at Citizens JMP
Aug 5, 2025 02:35AM Citizens JMP Starts Quince Therapeutics Inc. (QNCX) at Market Outperform
Jul 15, 2025 07:44AM Lucid Capital Markets Starts Quince Therapeutics Inc. (QNCX) at Buy
Jul 10, 2025 04:05PM Quince Therapeutics names Dr. Hassan Abolhassani to advisory board
Jun 12, 2025 05:15PM Quince Therapeutics (QNCX) Prices $22M Share and Warrant Offering
May 13, 2025 05:25PM Cortexyme, Inc. (QNCX) Misses Q1 EPS by 15c
Mar 25, 2025 07:11AM Quince Therapeutics Inc. (QNCX) PT Lowered to $4 at D. Boral Capital
Mar 24, 2025 06:03AM Oppenheimer Starts Quince Therapeutics Inc. (QNCX) at Outperform
Feb 4, 2025 04:06PM Quince Therapeutics (QNCX) Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Dec 18, 2024 04:07PM Quince Therapeutics (QNCX) Files $200M Mixed Shelf
Dec 18, 2024 04:05AM Brookline Capital Markets Starts Quince Therapeutics Inc. (QNCX) at Buy
Nov 13, 2024 04:26PM Cortexyme, Inc. (QNCX) Misses Q3 EPS by 3c
Nov 12, 2024 04:05PM Quince Therapeutics (QNCX) Presents Data from Prior Phase 3 ATTeST Clinical Trial
Nov 11, 2024 04:05PM Quince Therapeutics (QNCX) Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial
Oct 29, 2024 06:48AM Rodman & Renshaw Starts Quince Therapeutics Inc. (QNCX) at Buy
Oct 22, 2024 07:18AM EF Hutton Starts Quince Therapeutics Inc. (QNCX) at Buy
Aug 15, 2024 07:01AM Quince Therapeutics (QNCX) Announces The Lancet Neurology Publication of Phase 3 ATTeST Trial of EryDex
Aug 13, 2024 05:56PM Cortexyme, Inc. (QNCX) Reports Q2 Loss of $0.64